The COVID-19 pandemic was an once-in-a-lifetime occurrence that had far-reaching health-care, economic, and societal consequences around the world. The health-care system in North America faced an immediate issue in estimating the demographics of COVID-19's impact. In the absence of precise data, a lockdown was enforced early, putting the health-care system under even more strain to care for non-COVID-19 patients who needed immediate attention. The lockdown had an immediate impact on logistics and supply lines, which had an impact on health-care delivery in the region. In the early stages of COVID-19, biobanking activities in Canada were considered a non-essential health care service, but as necessary research operations began, COVID-19–related studies were permitted and launched. Biobanking became a necessary service as a result of this development, allowing for faster COVID-19 research and the continuation of critical research operations. During the epidemic, navigating the scarce and frequently competing health-care supply chains was critical for continuous operational demands. biobanks have had to purchase extra personal protective equipment (PPE) to safeguard their personnel from COVID-19, and even employees have had to be regularly checked for suspected COVID-19 symptoms. Biobanks had to communicate and search globally for the materials they required to quickly collect and store specimens. Biobanks are critical in collecting and preserving biosamples such as plasma, serum, DNA and RNA, clinical data, and genomic data due to the large number of clinical trials related to COVID-19.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America biobanks market. The North America biobanks market is expected to grow at a good CAGR during the forecast period.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 875.19 Million |
| Market Size by 2028 | US$ 1,386.56 Million |
| CAGR (2021 - 2028) | 6.8% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product and Service
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
The North America Biobanks Market is valued at US$ 875.19 Million in 2021, it is projected to reach US$ 1,386.56 Million by 2028.
As per our report North America Biobanks Market, the market size is valued at US$ 875.19 Million in 2021, projecting it to reach US$ 1,386.56 Million by 2028. This translates to a CAGR of approximately 6.8% during the forecast period.
The North America Biobanks Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Biobanks Market report:
The North America Biobanks Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Biobanks Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Biobanks Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Biobanks Market
